Gender‐affirming hormone therapy and the risk of sex hormone‐dependent tumours in transgender individuals—A systematic review

  title={Gender‐affirming hormone therapy and the risk of sex hormone‐dependent tumours in transgender individuals—A systematic review},
  author={Thomas McFarlane and Jeffrey D. Zajac and Ada S. Cheung},
  journal={Clinical Endocrinology},
  pages={700 - 711}
Cancers are a leading cause of death worldwide, and transgender individuals are no exception. The effects of gender‐affirming hormone therapy (GAHT) on sex hormone‐dependent tumours are unclear. Therefore, this review seeks to determine whether tumour risk in transgender individuals differs from the general population, to guide clinical screening recommendations. 

Position statement on the hormonal management of adult transgender and gender diverse individuals

This work aims to provide general practitioners, physicians and other medical professionals with specific Australian recommendations for the hormonal and related management of adult TGD individuals.

Testosterone therapy considerations in estrogen, progesterone and androgen receptor positive breast cancer in a transgender male.

A 44-year-old premenopausal individual assigned female at birth but with a male gender identity, presented requesting masculinizing hormone therapy for long-standing gender dysphoria, and baseline blood tests and hormonal panel were within female reference ranges.

Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: A systematic review

Gender-affirming hormone therapy for transgender women includes estrogen and antiandrogens (cyproterone acetate, spironolactone, or gonadotropin-releasing hormone agonists). Both estrogen and antia...

Breast Cancer in Transgenders: Narrative Review

There are no international guidelines on screening and management of transgender patients but it appears that breast screening before cosmetic mastectomy, exposure to hormonal therapy for more than 5 years, and as per natal women screening guidelines should be offered to the patient with detailed discussion on the harms and benefits of the same.

Health considerations for transgender women and remaining unknowns: a narrative review

This narrative review aims to comprehensively summarize health considerations for transgender (trans) women and identify TW-related research areas that will provide answers to remaining unknowns surrounding TW’s health.

Potential immunological effects of gender-affirming hormone therapy in transgender people – an unexplored area of research

The scientific literature strongly suggests that sex-based differences in the functioning of the immune system are related to both X-linked genes and immune modulation by sex hormones, and it is crucial to ensure the positive health outcomes of trans people.

Cancer screening in the transgender population: a review of current guidelines, best practices, and a proposed care model

Current guidelines and practice patterns of cancer screening in transgender patients are covered, and evidence-based data is lacking, to draw from cis-gender screening guidelines to suggest best-practice screening approaches for transgender patients.



Triple negative breast cancer in a male‐to‐female transsexual

A case of an aggressive triple negative inflammatory breast cancer in a male‐to‐female transsexual with a complicated psychiatric history with significant antipsychotic use is reported.

The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?

Long standing beliefs of androgen suppression conferring a protective effect against prostate cancer development have been challenged by the literature citing adenocarcinoma development in the prostate of rodent models following combined estrogen and testosterone treatment.

Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy.

A male-to-female transgender woman who was diagnosed with metastatic prostate cancer, 31 years post-feminization is reported, a challenge in the treatment and follow-up of such patients.

Breast cancer in male-to-female (MtF) transgender patients: is hormone receptor negativity a feature?

A 41-year-old male-to-female (MtF) transgender patient presented with a symptomatic tender lump in the left breast and was referred to the oncologist for adjuvant chemotherapy and radiotherapy.

Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones.

The probability of a hormone-related tumor increases with the duration of exposure to cross-sex hormones and the aging of the population of transsexuals, so far only a few cases of hormone- related cancer in transsexuals are encountered.

Five new cases of breast cancer in transsexual persons

For adequate treatment and decisions on further cross‐sex hormone treatment it is important to have information on the staging and histology of the breast tumour (type, grade and receptor status), with an upcoming role for the androgen receptor status, especially in FtoM transsexual subjects with breast cancer who receive testosterone administration.

Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.

Cross-sex hormone treatment of transsexual subjects does not seem to be associated with an increased risk of malignant breast development, in either MtF or FtM transsexual individuals.

Recurrence and Progression of Meningioma in Male-to-Female Transgender Individuals During Exogenous Hormone Use

This report describes the third published case of a de novo World Health Organization Grade I meningioma occurring in a male-to-female transgender individual using exogenous hormones, and suggests that this association creates a relative contraindication for hormonal therapy in patients with diagnoses of mening ioma.

Meningiomas in three male‐to‐female transgender subjects using oestrogens/progestogens and review of the literature

The role of female sex hormones in the development and growth of meningiomas is supported and the decision to stop or continue cross‐sex hormone therapy in these particular patients should be carefully reconsidered individually.